UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

Core Insights - UNITY Biotechnology, Inc. has appointed Dr. Federico Grossi as chief medical officer, enhancing its executive leadership team [1][2] - Dr. Grossi's experience in clinical development and regulatory strategy is expected to support UNITY's strategic vision and accelerate the development of new therapeutics [3][4] Company Overview - UNITY is focused on developing therapeutics aimed at slowing, halting, or reversing diseases of aging, particularly in ophthalmologic and neurologic diseases [5] - The company is currently advancing UBX1325, a treatment for diabetic macular edema (DME), with key data readout from the Phase 2b ASPIRE study expected soon [3][4] Leadership Experience - Dr. Grossi has over 20 years of experience in the biotech industry, including significant roles in clinical strategy and development at Apellis Pharmaceuticals [3] - His leadership at Apellis included overseeing multiple concurrent clinical studies and leading to the approval of therapies such as EMPAVELI and SYFOVRE [3]